Magnetic resonance imaging (MRI) is a powerful noninvasive diagnostic technique that can differentiate normal tissue from diseased tissue and lesions. Magnetic resonance angiography (MRA) is a specialized MRI technique of gradually increasing importance that can provide angiography and can assess angiogenesis, blood volume and blood flow. [1] [2] [3] [4] Various contrast agents based on gadolinium ion (Gd 3+ ) complexes have been developed to enhance the MRI signal intensity and to improve the contrast-to-noise ratio in regions of interest by shortening the longitudinal relaxation time (T1) of water protons. However, the presently clinically-used contrast agents, such as Gd(DTPA) (gadolinium-diethylenetriaminepentaacetic acid: Magnevist ® ) and Gd(EOB-DTPA) (gadolinium-(4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic aciddisodium salt: Eovist ® ), are not suitable as blood pool contrast agents for the MRA technique due to their short plasma halflives caused by rapid elimination from the kidney and the liver, respectively, 5-9 and/or the characteristic of free extravasation into background muscles, 10 resulting in a rapid decrease of the contrast-to-noise ratio in blood vessels.
Introduction
Magnetic resonance imaging (MRI) is a powerful noninvasive diagnostic technique that can differentiate normal tissue from diseased tissue and lesions. Magnetic resonance angiography (MRA) is a specialized MRI technique of gradually increasing importance that can provide angiography and can assess angiogenesis, blood volume and blood flow. [1] [2] [3] [4] Various contrast agents based on gadolinium ion (Gd 3+ ) complexes have been developed to enhance the MRI signal intensity and to improve the contrast-to-noise ratio in regions of interest by shortening the longitudinal relaxation time (T1) of water protons. However, the presently clinically-used contrast agents, such as Gd(DTPA) (gadolinium-diethylenetriaminepentaacetic acid: Magnevist ® ) and Gd(EOB-DTPA) (gadolinium-(4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic aciddisodium salt: Eovist ® ), are not suitable as blood pool contrast agents for the MRA technique due to their short plasma halflives caused by rapid elimination from the kidney and the liver, respectively, [5] [6] [7] [8] [9] and/or the characteristic of free extravasation into background muscles, 10 resulting in a rapid decrease of the contrast-to-noise ratio in blood vessels.
For routine T1-weighted MRA examinations, the blood pool contrast agent is desired to have a long plasma half-life, and to be retained selectively in the intravascular space in order to obtain a high contrast-to-noise ratio, and to eliminate completely from the blood after MRI examinations. Macromolecular MRI contrast agents based on albumin, 11, 12 polymers [13] [14] [15] [16] [17] and dendrimers [18] [19] [20] have been developed as blood pool contrast agents, and were shown to have long plasma half-lives with a high relaxivity, which is a parameter representing the ability to act as a contrast agent. However, these macromolecular contrast agents have some limitations for clinical applications: (i) the possibility of eliciting an immune response due to the use of proteins and large molecules and/or (ii) significantly slow elimination from the body and subsequent metabolism, which could lead to the release of toxic by-products including free Gd 3+ . 14, [21] [22] [23] [24] [25] To address such limitations and potentials of these macromolecular MRI contrast agents, low molecular-weight gadolinium complexes have been chemically designed to bind noncovalently to substances like plasma proteins. 8, [26] [27] [28] [29] [30] As an example, due to its specific structure, MS-325 (Vasovist ® ) can bind strongly but noncovalently to human serum albumin (HSA), resulting in an extension of the plasma half-life (23.1 ± 2.9 min in rats 31 and approximately 2 -3 h in primates) 31 and an appropriate elimination from the organism. 32, 33 This long plasma half-life of MS-325 allows MRA imaging with substantial contrast-to-noise ratio to be performed for approximately 50 min in humans after administration. 34 As a result, the long imaging window permits multiple vascular stations or the same vascular bed to be scanned several times after a single injection, resulting in lower amounts of applied doses of contrast agents for MRA examinations. Furthermore, the long window also increases the overall image quality by controlling imaging parameters, for example, increasing the spatial resolution, the number of signal averages and the repetition time. [34] [35] [36] Similar results are difficult to obtain when one uses Magnevist ® with a plasma half-life of 15.4 ± 1.3 min in rats, 37 which demonstrates the effect of the increased plasma half-life. 34, 36 Thus, MS-325 was a superior blood pool contrast agent for the usage in MRA examination. However, the synthesis of MS-325 requires six steps, [37] [38] [39] which makes serial investigations of structurally modified derivatives rather difficult.
Based on previous studies, we considered that the balance of hydrophilicity and lipophilicity of a blood pool MRI contrast agent is the most important factor for controlling the plasma half-life and the elimination from an organism. Therefore, in this study, we introduce a novel and simple concept to vary and to control the partition coefficient (P) value of a gadolinium complex by the introduction of lipophilic groups and hydrophilic sulfonic acids, resulting in a negative net charge. In this article, we describe the molecular design, synthesis, characterization, in vitro and in vivo evaluations of six novel contrast agents: KMR-Sulfo1 -6.
Experimental

Reagents and apparatus
All chemicals and solvents were purchased from Tokyo Chemical Industry, Wako Pure Chemical Industries, or SigmaAldrich Chemical. Magnevist ® and human plasma were obtained from Nihon Schering and Kohjin Bio, respectively. All materials were used without further purification. 1 H NMR spectra were recorded on a JNM-LA300 (JEOL) instrument. HPLC purification was performed on an LC-918 recycling preparative HPLC instrument (Japan Analytical Industry) with a reversed-phase column (YMC-Pack ODS-A: 500 × 20 mm i.d., YMC). Mass spectrometry was performed using a Mariner ESI-TOF mass spectrometer (PerSeptive Biosystems) with methanol as the eluent. Inductively coupled plasma atomic emission spectrometry (ICP-AES) measurements were performed using an ICPS-8000 (Shimadzu).
The T1 measurements were performed using a 0.47 T NMS 120 Minispec NMR Analyzer (Bruker Optics). The MR images were recorded using a SIGNA EXCITE XI 1.5 T (GE Healthcare).
Synthesis
General procedure for ligand synthesis. To a solution of diethylenetriaminepentaacetic dianhydride (DTPA-ba; 1.0 eq.) in dry N,N-dimethylformamide, the specific primary amine derivative bearing sulfonic acid (2.0 eq.) was added and the mixture was stirred at 70˚C for 3 h under an Ar atmosphere. The reaction mixture was evaporated in vacuo. The residue was purified by reverse-phase column HPLC (RP-HPLC; methanol:water:trifluoroacetic acid = 100:66:0.5, v/v) to give compounds 1a -6a. A sealed tetramethylsilane (TMS) capillary was used as an external reference to obtain NMR spectra. 
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((2-(Carboxymethyl-(2-(carboxymethyl-((6-sulfo-naphthalen-2-ylcarbamoyl)methyl)amino)ethyl)amino)ethyl)-((6-sulfonaphthalen-2-ylcarbamoyl)methyl)amino)acetic acid (3a)
The standard procedure was employed with DTPAba (0.52 g, 1.5 mmol) and 7-amino-1,3-naphthalenedisulfonic acid monopotassium salt (1.0 g, 2.9 mmol) to afford, after RP-HPLC (4.5 mL/min, tR: 31 min), compound 4a (1. 
((2-(Carboxymethyl-(2-(carboxymethyl-((2,4-dimethyl-6-sulfophenylcarbamoyl)methyl)amino)ethyl)amino)ethyl)-((2,4-dimethyl-6-sulfo-phenylcarbamoyl)methyl)amino)acetic acid (5a).
The standard procedure was employed with DTPA-ba (0.89 g, 2.5 mmol) and 2,4-dimethylaniline-6-sulfonic acid (1.0 g, 5.0 mmol) to afford, after RP-HPLC (3.5 mL/min, tR: 41 min), compound 5a (1.5 g, 81%) as a white solid. δH (300 MHz; D2O) 2.12 (6H, s), 2.34 (6H, s), 2.75 -2.95 (8H, m), 3.21 (2H, s), 3.41 (4H, s), 3.51 (4H, s), 7.55 (2H, s), 7.94 (2H, s); m/z (ESI-TOF) calcd. for C30H39N5O14S2 (M-2H + ) 2-378.9; found 378.7.
((2-(Carboxymethyl-(2-(carboxymethyl-((1-sulfo-naphthalen-2-ylcarbamoyl)methyl)amino)ethyl)amino)ethyl)-((1-sulfonaphthalen-2-ylcarbamoyl)methyl)amino)acetic acid (6a).
The standard procedure was employed with DTPA-ba (0.80 g, 2.2 mmol) and 2-amino-1-naphthalene-sulfonic acid (1.0 g, 4.5 mmol) to afford, after RP-HPLC (3.5 mL/min, tR: 42 min), compound 6a (1.6 g, 88%) as a white solid. δH (300 MHz; D2O) 2.82 -3.00 (8H, m), 3 General procedure for gadolinium complex synthesis. To a solution of the ligand (1.0 eq.) in water, gadolinium(III) chloride hexahydrate (GdCl3·6H2O, 1.0 eq.) was added and the mixture was stirred at room temperature overnight. During the reaction, the pH of the solution was maintained at pH 6 by addition of dilute aqueous NaOH. The reaction mixture was then evaporated in vacuo and the residue was purified by RP-HPLC (methanol:water = 3:2, v/v) to give KMR-Sulfo1 -6. KMR-Sulfo1. The standard procedure was employed with compound 1a (1.0 g, 1.6 mmol) and GdCl3·6H2O (0.58 g, 1.6 mmol) to afford, after RP-HPLC (3.5 mL/min, tR: 43 min), KMR-Sulfo1 (1.1 g, 87%) as a white solid. m/z (ESI-TOF) calcd. for C20H32GdN5O14S2 (M-2H + ) 2- 
Relaxivity measurements
The T1 measurements of contrast agents, KMR-Sulfo1-6 and 
Partition coefficient measurements
Using pH 7.4 phosphate buffer saline (PBS), partition coefficients (P) of contrast agents were measured using the octanol/PBS system. Each contrast agent was equilibrated with PBS-saturated octanol and octanol-saturated PBS at room temperature for 1 h.
These two-phase solutions were centrifuged at 2000g for 20 min to ensure the layer separation. The PBS and octanol layers of these samples were digested and mineralized in a 3:1 v/v mixture of hydrochloric acid and nitric acid at 90˚C for 6 h. The gadolinium ion content of each sample was determined by ICP-AES to calculate the P value (P = (average [Gd] of octanol)/(average [Gd] of PBS)). These P value measurements were performed in triplicate for each contrast agent.
Pharmacokinetic study and measurements of plasma half-life
The maintenance and care of the experimental animals were in accordance with the guidelines set forth by the Keio University School of Medicine. The experiments were approved by the Animal Care and Use Committee and were specifically designed to minimize animal discomfort.
A clear solution of each contrast agent, KMR-Sulfo5, KMRSulfo6 and Magnevist ® , in water was injected (0.10 Gdmmol/kg) via the tail vein of male Crl:CD(SD) rats (Charles River Laboratories Japan), which were 3 weeks of age and were fully anesthetized with diethyl ether during the injection. The animals were sacrificed 0, 10, 30 min and 1, 2, 4, 6 and 12 h after the injection (3 animals for each time point). The organs, blood, liver, kidney, spleen and pancreas, were removed, weighed and dehydrated at 80˚C for 24 h. These samples were digested and mineralized in a 3:1 v/v mixture of hydrochloric acid and nitric acid at 100˚C for 24 h. The gadolinium ion content of each sample was determined by ICP-AES.
Blood contrast agent concentration data were analyzed to determine the plasma half-life (t1/2) of each contrast agent using the single exponential equation (Ct = C0·e -k·t ), where Ct and C0 is the blood concentration of contrast agents at time t and 0, respectively, and k is the elimination rate constant. 40 
Magnetic resonance imaging
All MRI experiments were performed with the rats in the supine position using a 1.5 T MRI equipped with a 40 mT/m gradient system and using a surface radio frequency coil for the wrist. 
Results and Discussion
Molecular design and synthesis
For a blood pool contrast agent, the following features are desired in order to improve the contrast-to-noise ratio of blood vessels of interest in MR images: (i) long plasma half-life, (ii) retention of the contrast agent in the intravascular space (keep leakage to extracellular space as small as possible), and (iii) complete elimination from the body after MRI examinations. To meet these requirements, we focused on controlling the balance between the lipophilicity and the hydrophilicity of a contrast agent to realize appropriate in vivo functionality and drug kinetics by avoiding too rapid excretions from the kidney and the liver.
We succeeded in designing and synthesizing the novel blood pool contrast agents of the KMR-Sulfo series by introducing a novel and simple concept, which allows one to incorporate into a low molecular-weight gadolinium complex two substituent groups bearing antithetic characteristics of water solubility, a lipophilic group and a hydrophilic functional group. The lipophilicity is a critical parameter to promote noncovalent binding of the contrast agent to the lipid binding sites of HSA that is known as a lipid transporter and exists in large amounts in the blood. 41, 42 This binding is expected to provide a long plasma half-life because HSA has a significantly long plasma half-life. 41, 43 Therefore, the rapid excretion of the contrast agent from the kidney and the liver could be prevented. To increase the lipophilicity of the contrast agent, we selected lipophilic groups such as alkyl chains or aromatic groups and covalently bound them to a highly hydrophilic gadolinium complex of Gd(DTPA) as a side chain (Fig. 1) .
As the hydrophilic functional group, a sulfonic acid residue was chosen because of its large dissociation constant, resulting in a negative charge under physiological pH conditions. This negative net charge is essential for avoiding rapid renal excretion because the kidney can especially and rapidly excrete positively charged materials due to the negative charge of the renal glomerulus. 44 Furthermore, the commercial availability of various sulfonated compounds allowed us to perform a serial investigation of controlling the balance between the lipophilicity and the hydrophilicity of new potential blood pool contrast agents. As a physical parameter to assess the balance between the lipophilicity and the hydrophilicity of the sulfonated starting materials and the serially synthesized 1161 ANALYTICAL SCIENCES OCTOBER 2007, VOL. 23 contrast agents, we used the octanol-PBS partition coefficient (P) value in this study.
The compounds of the KMR-Sulfo series were synthesized by reacting diethylenetriaminepentaacetic acid bisanhydride (DTPA-ba) with the primary amine derivatives 1 -6, followed by chelation with Gd 3+ under aqueous condition (Fig. 1) . The primary amine derivatives 1 -6 included a lipophilic group and one or two sulfonic acids and had various P values to synthesize gadolinium complexes that bore a wide P value range. The log P values of the amine derivatives 1 -6 were between -2.96 ± 0.42 and 1.32 ± 0.25 (Table 1) , which were theoretically calculated values based on the ACD/log P software in the SciFinder Scholar TM database. The correspondingly synthesized gadolinium complexes KMR-Sulfo1 -6 showed experimentally determined log P values between -1.40 ± 0.19 and 0.19 ± 0.04 (Table 1) . When comparing the estimated P values of the primary amine derivatives 1 -6 with the experimental P values of the corresponding KMR-Sulfo1 -6, a linear correlation could be found, as expected according to our molecular design principle (Fig. 2) . By using this convenient two-step synthesis route, we have succeeded in synthesizing a series of gadolinium complexes (KMR-Sulfo series) featuring various lipophilicities and negative charges. All synthesized KMR-Sulfo compounds were confirmed to have sufficient water solubility, which is required in order to use them for in vivo applications.
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ANALYTICAL SCIENCES OCTOBER 2007, VOL. 23 Theoretically calculated values of compounds 1 -6, which were used in the corresponding KMR-Sulfo1 -6 syntheses (Fig. 1) , based on the ACD/log P software in the SciFinder Scholar TM database. b. Experimentally determined values using KMR-Sulfo1 -6. c. Numeric character in parentheses represents the r1 change (%) compared to each r1 value measured in PBS. d. Not measured. e. From Ref. 37 . Measured using the butanol/PBS system.
Relaxivity measurement to estimate in vitro protein binding ability
As mentioned above, a high protein binding ability is required to achieve a long plasma half-life and subsequent selective retention of the blood pool contrast agent in the intravascular space. Therefore, the protein binding ability of each KMRSulfo compound was assessed by measuring its longitudinal relaxivity (r1) value in the presence of proteins (HSA or blood plasma). It is known that the binding of contrast agents to large molecules such as HSA enhances the efficacy of the electronnuclear interaction between the gadolinium ion and water protons due to a decrease of molecular tumbling of the proteinbound agent and to an increase of the correlation time between them, 25, 45 leading to short T1 and bright blood vessels on MRI images. 35, 46 For this reason, an experimentally observed increase of the r1 value of the KMR-Sulfo compounds indicates a binding between the contrast agent and HSA or other plasma proteins (Table 1) . Although a clear relationship between the P values and the changes of the r1 values in the absence and presence of HSA could not be observed, the r1 values were largely enhanced by over 30% in 4.5% HSA PBS in the case of KMR-Sulfo3 -6 and by over 40% in human plasma in the case of KMR-Sulfo4 -6 (Table 1) . For comparison purposes, the identical binding assay was also performed using the clinicallyapplied hydrophilic contrast agent Magnevist ® , which does not include any lipophilic side chains. In this case, the r1 values were enhanced by 13.5% in 4.5% HSA PBS and by 20.6% in human plasma. The results clearly indicate the superior characteristics of KMR-Sulfo3 -6 regarding the protein binding ability. Furthermore, in the case of KMR-Sulfo1 -5, no large differences in the r1 values were observed between the results obtained in 4.5% HSA PBS and in human plasma. However, only in the case of KMR-Sulfo6, the r1 value significantly increased with the use of human plasma. This result suggests that KMR-Sulfo6 can also strongly bind to other plasma proteins besides HSA, indicating a potential risk of inhibiting the activities of vital blood proteins.
Pharmacokinetic study and measurement of plasma half-life
When incorporating excess lipophilic groups into a gadolinium complex, the plasma half-life is generally shortened compared to non-modified gadolinium complexes such as Magnevist ® . This change is because of facilitated hepatobiliary excretion, mainly from the liver. 37 Thus, optimal lipophilicity is required to design a low-molecular-weight blood pool contrast agent.
KMR-Sulfo5 and KMR-Sulfo6, which showed large P values and excellent protein binding abilities among all the KMR-Sulfo compounds, were administrated to rats via the tail vein to investigate the drug kinetics and the plasma half-life by measuring the gadolinium content of each organ, and such content was defined as grams of gadolinium ions per gram of organ, using an ICP-AES apparatus. Identical experiments were performed with Magnevist ® as a reference compound. Compared to Magnevist ® , a slightly larger amount of excretion of KMR-Sulfo5 from the liver and an obviously slower excretion of KMR-Sulfo6 from the kidney were revealed by these in vivo pharmacokinetic studies (Fig. 3) . Even though the details of the protein binding modality and mechanism of the KMR-Sulfo compounds are still unknown, the excretions from the kidney and the liver are assumed to occur only for the fraction of the contrast agents unbound to plasma proteins, especially for HSA, because HSA has a significantly long plasma half-life. 41, 43 The observed plasma half-lives of 25.7 and 32.7 min in healthy rats with the administration of KMR-Sulfo5 and KMRSulfo6, respectively, were longer compared to the reference compound Magnevist ® that had a value of 17.6 min in rats (Table 1 and Fig. 3 ). These longer plasma half-lives of KMRSulfo5 and KMR-Sulfo6 were attributed to the appropriate control of the balance of lipophilicity and hydrophilicity using aromatic groups and sulfonic acids, which are able to suppress the rapid excretions from the kidney and the liver by allowing the contrast agents to bind to plasma proteins. The plasma halflife values of KMR-Sulfo5 and KMR-Sulfo6 were also superior to that of an existing blood pool contrast agent, MS-325, which has a plasma half-life of 23.1 ± 2.88 min in rats. 31 Furthermore, the complete elimination within 12 h after the administration of 1163 ANALYTICAL SCIENCES OCTOBER 2007, VOL. 23 each contrast agent from the blood, liver, kidney, spleen and pancreas was confirmed by ICP-AES measurements (data not shown). Although KMR-Sulfo6 has a longer plasma half-life compared to KMR-Sulfo5, from the perspective of functionality and safety, KMR-Sulfo5 has the greater potential as a blood pool contrast agent.
Magnetic resonance imaging
The results of the relaxivity measurements in PBS showed that all KMR-Sulfo compounds had r1 values (between 5.4 and 5.9 mM -1 s -1 ) approximately equivalent to that of the clinicallyused contrast agent Magnevist ® (5.8 mM -1 s -1 ). From these results, the potential usability of KMR-Sulfo1 -6 as a contrast agent for MRI was confirmed (Table 1) .
T1-weighted MR images were recorded after the intravenous administration of Magnevist ® or KMR-Sulfo5, which was selected as the most promising blood pool contrast agent candidate due to its long plasma half-life generated by binding mainly to HSA. The MR imaging of the rats before and at various time points after the administration of the contrast agents showed a significant enhancement of the signal intensity in the blood vessels up to 15 min after administration in the case of KMR-Sulfo5, and an expected significantly rapid renal excretion from the blood pool in the case of Magnevist ® due to its high hydrophilicity and subsequent short plasma half-life (Figs. 4 and 5) . The signal intensities in the blood lumen area on the MR images gradually decreased and reached their original level 60 min after the administration of Magnevist ® or KMR-Sulfo5. However, the slope of the elimination curve of KMR-Sulfo5 was significantly less steep than that of the curve of Magnevist ® (Fig. 5) , suggesting the longer retention of KMRSulfo5 in the blood pool.
In conclusion, we have demonstrated that the rational design and the synthesis of a series of gadolinium complexes with well-balanced lipophilicity and hydrophilicity based on commercially available building blocks, are promising approaches to novel potential blood pool MRI contrast agents. In particular, KMR-Sulfo5 was found to have excellent practical properties needed to act as a blood pool contrast agent. More detailed studies are necessary to fully assess the toxicity of KMR-Sulfo5 for clinical applications. 
